Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Misses Estimates By $0.03 EPS

Kura Oncology (NASDAQ:KURA) announced its earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03), Briefing.com reports. During the same period in the prior year, the business posted ($0.50) EPS. Kura Oncology’s revenue was up .0% compared to the same quarter last year.

Kura Oncology Stock Up 0.2 %

Shares of NASDAQ:KURA opened at $20.63 on Friday. The firm’s 50 day simple moving average is $20.66 and its 200 day simple moving average is $15.99. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17.

Analyst Upgrades and Downgrades

KURA has been the topic of a number of research reports. Wedbush reiterated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday. JMP Securities upped their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a research report on Wednesday, January 31st. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Friday. Finally, StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.28.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.